[Activation of bradykinin formation cascade on receiving autologous blood transfusion through a white cell-reduction filter in a patient treated with an ACE inhibitor].
We have experienced a case of anaphylactoid reaction on receiving autologous blood transfusion through a WBC filter for packed red blood cell (PRBC). The patient was a 71-year-old man with a history of hypertension treated with oral antihypertensive drug; enalapril, an angiotensin converting enzyme (ACE) inhibitor, who received anesthesia for Y-graft replacement. Autologous blood was obtained after the induction of general anesthesia in the operating room. Upon starting to return the stored blood with an unintentional use of a WBC filter, arterial blood pressure (ABP) fell within the first minute of the transfusion. We obtained three blood samples; pre-filtered blood (PRE), postfiltered blood (POST) and arterial blood (CIRC) after the event, and analyzed concentrations of bradykinin (BK), high molecular weight kininogen (HMWK) and high molecular weight kininogen-light chain (HMWK-LC). BK was higher in POST than in PRE. HMWK was lower in POST than in PRE, while HMWK-LC was higher in POST than in PRE. HMWK in CIRC was lower than in PRE, and HMWK-LC was higher in CIRC than in PRE. HMWK and HMWK-LC changes after the event suggest that BK formation cascade in the patient was activated on receiving the transfusion. ACE inhibitors were reported to augment such activation. The WBC filter has the negatively charged surface on filteration material and may activate the cascade. While WBC filters can avoid transfusion related reactions, hemodynamic responses should be watched closely in patients treated with ACE inhibitors.
Ishikawa
T
T
Department of Anesthesiology and Intensive Care, Hokkaido University School of Medicine, Sapporo.
Niida
Y
Y
Kaneko
H
H
Okamura
A
A
Kemmotsu
O
O
D000368:Aged; D000707:Anaphylaxis / Q000209:etiology*; D000768:Anesthesia, General; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000009:adverse effects*; D000959:Antihypertensive Agents / Q000009:adverse effects; D001161:Arteriosclerosis / Q000601:surgery; D001804:Blood Transfusion, Autologous / Q000009:adverse effects*; D001920:Bradykinin / Q000378:metabolism*; D004656:Enalapril / Q000009:adverse effects; D006801:Humans; D007704:Kininogens / Q000378:metabolism; D007937:Leukapheresis / Q000009:adverse effects* / Q000295:instrumentation; D008297:Male
D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D007704:Kininogens; D004656:Enalapril; D001920:Bradykinin